Vertical Group

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating various neurological diseases. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation (VNS) to address conditions such as tinnitus, chronic pain, and rehabilitation for stroke survivors. Its notable products include the Serenity System, designed specifically for tinnitus treatment, and the Vivistim device, which is FDA approved for assisting ischemic stroke survivors with moderate to severe upper limb impairment. Through its innovative approaches, MicroTransponder aims to enhance recovery and improve the quality of life for individuals affected by these neurological conditions.

Route 92 Medical, established in 2015 and headquartered in San Mateo, California, specializes in the development of innovative medical devices for stroke treatment. Their flagship product is a stealthy catheter designed for rapid and efficient removal of blood clots during acute ischemic stroke, aiming to improve patient outcomes and enhance recovery. Additionally, the company offers a rapid aspiration thrombectomy system and an intra-cerebral implant delivery system, further expanding their capabilities in stroke care.

Route 92 Medical, established in 2015 and headquartered in San Mateo, California, specializes in the development of innovative medical devices for stroke treatment. Their flagship product is a stealthy catheter designed for rapid and efficient removal of blood clots during acute ischemic stroke, aiming to improve patient outcomes and enhance recovery. Additionally, the company offers a rapid aspiration thrombectomy system and an intra-cerebral implant delivery system, further expanding their capabilities in stroke care.

Luminopia is a company focused on developing innovative treatments for significant neuro-visual disorders, particularly amblyopia, commonly known as lazy eye, which is a leading cause of vision loss in children. By creating engaging digital therapeutics, Luminopia aims to provide effective solutions that are rigorously evaluated for FDA approval. Their flagship product, Luminopia One, leverages binocular vision techniques to address amblyopia, enabling healthcare professionals to offer new treatment options for affected patients. Partnering with Boston Children’s Hospital, Luminopia is at the forefront of pioneering advanced therapeutic approaches that enhance patient care in the field of pediatric vision health.

Luminopia is a company focused on developing innovative treatments for significant neuro-visual disorders, particularly amblyopia, commonly known as lazy eye, which is a leading cause of vision loss in children. By creating engaging digital therapeutics, Luminopia aims to provide effective solutions that are rigorously evaluated for FDA approval. Their flagship product, Luminopia One, leverages binocular vision techniques to address amblyopia, enabling healthcare professionals to offer new treatment options for affected patients. Partnering with Boston Children’s Hospital, Luminopia is at the forefront of pioneering advanced therapeutic approaches that enhance patient care in the field of pediatric vision health.

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating various neurological diseases. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation (VNS) to address conditions such as tinnitus, chronic pain, and rehabilitation for stroke survivors. Its notable products include the Serenity System, designed specifically for tinnitus treatment, and the Vivistim device, which is FDA approved for assisting ischemic stroke survivors with moderate to severe upper limb impairment. Through its innovative approaches, MicroTransponder aims to enhance recovery and improve the quality of life for individuals affected by these neurological conditions.

Carlsmed is a medical technology company based in San Diego, California, founded in 2018. It specializes in developing innovative solutions for spine surgery, notably through its proprietary aprevo™ digital-to-device 3-D printed implant system. This system is recognized as the first surgical implant to receive FDA designation as a breakthrough technology, reflecting its potential to enhance patient outcomes. Carlsmed focuses on personalized medicine, particularly in lumbar fusion surgery, by utilizing machine learning and historical outcomes data to tailor treatments for complex adult spinal deformities. The company aims to improve surgical results while also reducing healthcare costs associated with spine surgery, making it a valuable partner for hospitals and surgeons nationwide.

Route 92 Medical, established in 2015 and headquartered in San Mateo, California, specializes in the development of innovative medical devices for stroke treatment. Their flagship product is a stealthy catheter designed for rapid and efficient removal of blood clots during acute ischemic stroke, aiming to improve patient outcomes and enhance recovery. Additionally, the company offers a rapid aspiration thrombectomy system and an intra-cerebral implant delivery system, further expanding their capabilities in stroke care.

Carlsmed is a medical technology company based in San Diego, California, founded in 2018. It specializes in developing innovative solutions for spine surgery, notably through its proprietary aprevo™ digital-to-device 3-D printed implant system. This system is recognized as the first surgical implant to receive FDA designation as a breakthrough technology, reflecting its potential to enhance patient outcomes. Carlsmed focuses on personalized medicine, particularly in lumbar fusion surgery, by utilizing machine learning and historical outcomes data to tailor treatments for complex adult spinal deformities. The company aims to improve surgical results while also reducing healthcare costs associated with spine surgery, making it a valuable partner for hospitals and surgeons nationwide.

Biorez, Inc. is a medical device company focused on developing bioresorbable scaffold implants aimed at enhancing tissue regeneration in vivo. Founded in 2008 and based in New Haven, Connecticut, the company offers innovative products such as the L-C Ligament, designed for anterior cruciate ligament (ACL) reconstruction, which eliminates the need for donor tissue harvesting and serves as a superior alternative to cadaver-based materials. Biorez utilizes patented technology involving a degradable polymer, PLLA, in its orthopedic implants to promote the regeneration and augmentation of soft tissue. Among its offerings is the biorez GRAFT, a FDA-cleared device for soft tissue augmentation of the rotator cuff. The company’s bioinductive implants stabilize surgical repairs while the body rebuilds its musculoskeletal tissue, thereby facilitating quicker and safer recovery for patients and providing surgeons with effective tools to improve soft tissue repair outcomes.

Biorez, Inc. is a medical device company focused on developing bioresorbable scaffold implants aimed at enhancing tissue regeneration in vivo. Founded in 2008 and based in New Haven, Connecticut, the company offers innovative products such as the L-C Ligament, designed for anterior cruciate ligament (ACL) reconstruction, which eliminates the need for donor tissue harvesting and serves as a superior alternative to cadaver-based materials. Biorez utilizes patented technology involving a degradable polymer, PLLA, in its orthopedic implants to promote the regeneration and augmentation of soft tissue. Among its offerings is the biorez GRAFT, a FDA-cleared device for soft tissue augmentation of the rotator cuff. The company’s bioinductive implants stabilize surgical repairs while the body rebuilds its musculoskeletal tissue, thereby facilitating quicker and safer recovery for patients and providing surgeons with effective tools to improve soft tissue repair outcomes.

Hinge Health, established in 2015, specializes in digital healthcare solutions for musculoskeletal disorders, primarily targeting back and joint pains. The company offers wearable sensor technology, tablet computers, and support services, guiding users through physical therapy and weight loss activities. Their solutions are designed to be accessible and convenient, serving both individuals and businesses. Hinge Health's headquarters are in San Francisco, with additional offices in Chicago, Minneapolis, Portland, and London.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, that specializes in innovative solutions for treating carotid artery disease. Founded in 2007, the company has developed a unique approach known as transcarotid artery revascularization (TCAR), which aims to reduce the risk of stroke and enhance patient safety during procedures. Silk Road Medical's product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which allows for direct access to the common carotid artery while temporarily reversing blood flow to protect the brain. Additionally, the ENROUTE Transcarotid Stent System and the ENHANCE Transcarotid Peripheral Access Kit support the TCAR procedure by facilitating safe and effective treatment. Through its minimally invasive techniques, Silk Road Medical seeks to establish TCAR as the standard of care for carotid artery disease, demonstrating improved clinical outcomes and reduced complications associated with traditional methods.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating dialysis solutions for patients and healthcare providers. The company has developed the Tablo system, a hemodialysis machine designed for both acute and chronic care settings. Tablo features a compact console with integrated water purification, on-demand dialysate production, and advanced connectivity capabilities, including wireless data and sensor-based automation. This design aims to simplify the complexities and costs associated with dialysis, making it suitable for use in hospitals, dialysis clinics, and home settings. Originally founded as Home Dialysis Plus, Ltd. in 2003, the company rebranded to Outset Medical, Inc. in January 2015.

Hinge Health, established in 2015, specializes in digital healthcare solutions for musculoskeletal disorders, primarily targeting back and joint pains. The company offers wearable sensor technology, tablet computers, and support services, guiding users through physical therapy and weight loss activities. Their solutions are designed to be accessible and convenient, serving both individuals and businesses. Hinge Health's headquarters are in San Francisco, with additional offices in Chicago, Minneapolis, Portland, and London.

Route 92 Medical, established in 2015 and headquartered in San Mateo, California, specializes in the development of innovative medical devices for stroke treatment. Their flagship product is a stealthy catheter designed for rapid and efficient removal of blood clots during acute ischemic stroke, aiming to improve patient outcomes and enhance recovery. Additionally, the company offers a rapid aspiration thrombectomy system and an intra-cerebral implant delivery system, further expanding their capabilities in stroke care.

Suture Concepts provides solutions for physicians who practice in a cost-conscious environment. They also provide solutions for securing soft tissue to other tissues, the bone, or medical devices.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, that specializes in innovative solutions for treating carotid artery disease. Founded in 2007, the company has developed a unique approach known as transcarotid artery revascularization (TCAR), which aims to reduce the risk of stroke and enhance patient safety during procedures. Silk Road Medical's product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which allows for direct access to the common carotid artery while temporarily reversing blood flow to protect the brain. Additionally, the ENROUTE Transcarotid Stent System and the ENHANCE Transcarotid Peripheral Access Kit support the TCAR procedure by facilitating safe and effective treatment. Through its minimally invasive techniques, Silk Road Medical seeks to establish TCAR as the standard of care for carotid artery disease, demonstrating improved clinical outcomes and reduced complications associated with traditional methods.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating dialysis solutions for patients and healthcare providers. The company has developed the Tablo system, a hemodialysis machine designed for both acute and chronic care settings. Tablo features a compact console with integrated water purification, on-demand dialysate production, and advanced connectivity capabilities, including wireless data and sensor-based automation. This design aims to simplify the complexities and costs associated with dialysis, making it suitable for use in hospitals, dialysis clinics, and home settings. Originally founded as Home Dialysis Plus, Ltd. in 2003, the company rebranded to Outset Medical, Inc. in January 2015.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating dialysis solutions for patients and healthcare providers. The company has developed the Tablo system, a hemodialysis machine designed for both acute and chronic care settings. Tablo features a compact console with integrated water purification, on-demand dialysate production, and advanced connectivity capabilities, including wireless data and sensor-based automation. This design aims to simplify the complexities and costs associated with dialysis, making it suitable for use in hospitals, dialysis clinics, and home settings. Originally founded as Home Dialysis Plus, Ltd. in 2003, the company rebranded to Outset Medical, Inc. in January 2015.

Suture Concepts provides solutions for physicians who practice in a cost-conscious environment. They also provide solutions for securing soft tissue to other tissues, the bone, or medical devices.

Monteris Medical, Inc. is a medical device company specializing in the development and marketing of innovative technologies for the treatment of brain diseases. Founded in 1999 and based in Plymouth, Minnesota, with additional offices in Minneapolis and Winnipeg, the company focuses on minimally-invasive, MRI-guided, and robotically controlled neurosurgical procedures. Its flagship product, the NeuroBlate System, utilizes focused laser energy to safely ablate pathological brain lesions, such as tumors, while minimizing damage to surrounding healthy tissue. Monteris Medical also provides various stereotactic anchoring devices and stabilization systems for enhanced precision during image-guided procedures. The company markets its products directly to neurosurgeons in the United States, aiming to improve surgical outcomes through advanced technology.

Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.

AtheroMed, Inc. is a medical device company based in Menlo Park, California, which specializes in developing catheter-based treatments for peripheral arterial disease (PAD). Founded in 2006, AtheroMed's innovative systems address a range of vessel sizes, from small arteries at the ankle to larger ones above the knee. The company aims to improve patient outcomes through its targeted therapies, facilitating more effective treatment options for individuals suffering from PAD.

Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, that specializes in innovative solutions for treating carotid artery disease. Founded in 2007, the company has developed a unique approach known as transcarotid artery revascularization (TCAR), which aims to reduce the risk of stroke and enhance patient safety during procedures. Silk Road Medical's product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which allows for direct access to the common carotid artery while temporarily reversing blood flow to protect the brain. Additionally, the ENROUTE Transcarotid Stent System and the ENHANCE Transcarotid Peripheral Access Kit support the TCAR procedure by facilitating safe and effective treatment. Through its minimally invasive techniques, Silk Road Medical seeks to establish TCAR as the standard of care for carotid artery disease, demonstrating improved clinical outcomes and reduced complications associated with traditional methods.

AtheroMed, Inc. is a medical device company based in Menlo Park, California, which specializes in developing catheter-based treatments for peripheral arterial disease (PAD). Founded in 2006, AtheroMed's innovative systems address a range of vessel sizes, from small arteries at the ankle to larger ones above the knee. The company aims to improve patient outcomes through its targeted therapies, facilitating more effective treatment options for individuals suffering from PAD.

Flexuspine is a Pittsburgh-based company specializing in spinal devices that provide innovative alternatives to traditional lumbar fusion. Established in 2003, it focuses on developing a total spine disc replacement system designed to restore mobility to affected segments of the lumbar spine. Flexuspine's flagship product is a functional spinal unit that comprises both an interbody disc component and a posterior dynamic resistance component, which work together to replicate the natural movement of the spine. By offering these advanced solutions, Flexuspine aims to enhance the quality of life for patients undergoing spinal surgery.

Suture Concepts provides solutions for physicians who practice in a cost-conscious environment. They also provide solutions for securing soft tissue to other tissues, the bone, or medical devices.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

ENTrigue Surgical is a company focused on advancing sinus surgery through the development of innovative medical devices and instruments. Specializing in otolaryngology techniques, the company aims to improve the efficiency, effectiveness, and comfort of surgical procedures for both surgeons and patients. By rethinking traditional methods, ENTrigue Surgical seeks to enhance patient outcomes and streamline surgical practices, positioning itself as a forward-thinking entity in the field of sinus surgery.

PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

OncoMed Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, focused on discovering and developing innovative therapeutics targeting the biological mechanisms underlying cancer growth, resistance, recurrence, and metastasis. The company is advancing several therapeutic candidates, including Navicixizumab, a bispecific monoclonal antibody designed to target Delta-like ligand 4 and vascular endothelial growth factor, which has undergone clinical trials for advanced solid tumors, metastatic colorectal cancer, and platinum-resistant ovarian cancer. Additionally, OncoMed is developing Etigilimab, an anti-TIGIT monoclonal antibody that is currently in clinical trials for advanced or metastatic solid tumors. The company aims to provide new treatment alternatives by leveraging its understanding of cancer stem cells, which are critical to tumor initiation. OncoMed has established strategic alliances with leading pharmaceutical companies, including Celgene Corporation and Bayer Pharma AG, to facilitate the discovery and development of novel therapeutics. Founded in 2004, OncoMed Pharmaceuticals operates as a subsidiary of Mereo BioPharma Group plc.

ForteBio is a life science company that specializes in developing analytical systems for the rapid and real-time quantification and characterization of proteins and their interactions. The company offers a range of instruments known as the Octet family, designed to provide scientists with detailed information about biomolecular interactions in micro-volume sample sizes. These systems facilitate the analysis of proteins, peptides, DNA, RNA, and small molecules in a microplate format. Among its key products are the Octet RED, which enables quantitation and kinetic analysis while supporting small molecule screening, as well as the Octet Q and QK models, which also focus on quantitation and kinetics. Through these advanced tools, ForteBio aims to enhance research capabilities in the field of biomolecular interactions.

Proteolix is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies aimed at targeting protein degradation pathways to treat cancer and autoimmune diseases. The company’s lead product is a highly specific proteasome inhibitor, which represents a novel class of therapeutics being evaluated for safety and efficacy in multiple myeloma and other malignancies. In addition to this, Proteolix is developing a diverse pipeline of proteasome inhibitors, including both an oral formulation and a selective immunoproteasome inhibitor. These advancements aim to provide healthcare professionals with effective treatments for various hematologic cancers, thereby improving patient outcomes.

Meritage Pharma, Inc. is a pharmaceutical company based in San Diego, California, specializing in the development of prescription products aimed at treating gastrointestinal and atopic diseases. Founded in 2008, the company focuses on innovative therapies for conditions such as eosinophilic esophagitis, an allergic inflammation of the esophagus. Its lead product candidate is an oral formulation of budesonide, a glucocorticoid steroid known for its effectiveness in managing allergic reactions and inflammation. Additionally, Meritage Pharma offers budesonide as an active pharmaceutical ingredient for various conditions, including pediatric asthma, allergic rhinitis, and Crohn’s disease, thereby addressing a range of health issues associated with allergic inflammation.

Tepha, Inc. is a medical device company based in Lexington, Massachusetts, specializing in the development and manufacturing of components derived from proprietary biomaterial technology. Incorporated in 1998, Tepha focuses on creating innovative products based on polyhydroxyalkanoates, a new class of absorbable biomaterials engineered using recombinant DNA technology. The company's offerings include monofilament sutures for soft tissue approximation, monofilament meshes for various surgical applications such as hernia and pelvic floor repair, and a P4HB regenerative polymer scaffold for treating stress urinary incontinence. Additionally, Tepha produces surgical films for tissue support and composite meshes designed to minimize tissue attachment. The advanced properties of Tepha's biomaterials, including flexibility, elasticity, biocompatibility, and tensile strength, position the company to address unmet needs in the medical device industry across multiple fields.

BioSET, Inc., founded in 2001 and based in Rockville, Maryland, specializes in the research and development of synthetic bioactive peptides aimed at enhancing bone and soft tissue repair. The company creates proprietary therapeutic peptides utilized as medical devices in orthobiologics applications. Its notable product, Amplex, is an implantable device that combines a peptide with a synthetic ceramic scaffold, designed for use in spinal fusion surgeries and other orthopedic procedures. Additionally, BioSET develops products for sports medicine and creates peptide signaling molecules along with various scaffold biomaterials for applications in trauma, fracture repair, and soft tissue treatments. As of February 2015, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, that specializes in innovative solutions for treating carotid artery disease. Founded in 2007, the company has developed a unique approach known as transcarotid artery revascularization (TCAR), which aims to reduce the risk of stroke and enhance patient safety during procedures. Silk Road Medical's product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which allows for direct access to the common carotid artery while temporarily reversing blood flow to protect the brain. Additionally, the ENROUTE Transcarotid Stent System and the ENHANCE Transcarotid Peripheral Access Kit support the TCAR procedure by facilitating safe and effective treatment. Through its minimally invasive techniques, Silk Road Medical seeks to establish TCAR as the standard of care for carotid artery disease, demonstrating improved clinical outcomes and reduced complications associated with traditional methods.

Bacchus Vascular, Inc. is a medical device company based in Santa Clara, California, specializing in the treatment of occlusive vascular disease. Founded in 1999, the company develops innovative therapeutic solutions for interventional radiologists and vascular surgeons in the United States. One of its key products is the TRELLIS-8 Peripheral Infusion System, which features an isolated thrombolysis catheter designed for the targeted delivery of clot-dissolving drugs to treat conditions such as deep vein thrombosis and arterial occlusions. Additionally, Bacchus Vascular is involved in procedures for the percutaneous removal of blood clots from both dialysis and peripheral grafts, as well as native arteries and veins, further addressing the needs of patients with vascular complications.

PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

Elron Ventures is a venture capital firm based in Tel Aviv, Israel, founded in 1962. It specializes in seed and early-stage investments, focusing primarily on sectors such as enterprise software, cybersecurity, and medical technology. The firm is committed to transforming promising ideas into global industry leaders and has a notable history of successful investments and mergers and acquisitions. Elron Ventures has played a significant role in the Israeli innovation landscape, having been a founder and early investor in a variety of companies, including those in healthcare, defense, telecommunications, and medical devices. The firm's investment strategy emphasizes opportunities within Israel, reflecting its dedication to supporting local entrepreneurial talent.

Galil Medical Ltd. specializes in developing cryotherapy solutions aimed at treating various medical conditions across multiple specialties. Founded in 1996 and headquartered in Yokneam, Israel, with additional offices in Arden Hills, Minnesota, the company provides advanced cryosurgical systems that utilize compressed Argon gas to generate sub-zero temperatures for the cryosurgical ablation of both benign and cancerous tumors. Their product lineup includes the Visual-ICE system, which allows for precise control to protect critical anatomy, as well as the SeedNet and Presice systems designed for minimally invasive percutaneous procedures. Galil Medical's offerings extend to ultra-thin needles, thermal sensors, and other accessories that enhance the efficacy of their treatments. Their technologies are utilized in the management of conditions such as kidney, prostate, liver, lung, and breast cancers, among others. The company operates as a subsidiary of BTG plc, reflecting its integration into a broader healthcare framework.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Suture Concepts provides solutions for physicians who practice in a cost-conscious environment. They also provide solutions for securing soft tissue to other tissues, the bone, or medical devices.

PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

ForteBio is a life science company that specializes in developing analytical systems for the rapid and real-time quantification and characterization of proteins and their interactions. The company offers a range of instruments known as the Octet family, designed to provide scientists with detailed information about biomolecular interactions in micro-volume sample sizes. These systems facilitate the analysis of proteins, peptides, DNA, RNA, and small molecules in a microplate format. Among its key products are the Octet RED, which enables quantitation and kinetic analysis while supporting small molecule screening, as well as the Octet Q and QK models, which also focus on quantitation and kinetics. Through these advanced tools, ForteBio aims to enhance research capabilities in the field of biomolecular interactions.

PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

OncoMed Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, focused on discovering and developing innovative therapeutics targeting the biological mechanisms underlying cancer growth, resistance, recurrence, and metastasis. The company is advancing several therapeutic candidates, including Navicixizumab, a bispecific monoclonal antibody designed to target Delta-like ligand 4 and vascular endothelial growth factor, which has undergone clinical trials for advanced solid tumors, metastatic colorectal cancer, and platinum-resistant ovarian cancer. Additionally, OncoMed is developing Etigilimab, an anti-TIGIT monoclonal antibody that is currently in clinical trials for advanced or metastatic solid tumors. The company aims to provide new treatment alternatives by leveraging its understanding of cancer stem cells, which are critical to tumor initiation. OncoMed has established strategic alliances with leading pharmaceutical companies, including Celgene Corporation and Bayer Pharma AG, to facilitate the discovery and development of novel therapeutics. Founded in 2004, OncoMed Pharmaceuticals operates as a subsidiary of Mereo BioPharma Group plc.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

Velocimed was founded by a group of well known medical entrepreneurs. The company's founders envisioned a company that would become a global leader in the identification and development of innovative technologies with the power to improve the lives of patients whose clinical needs are not being met. Lead by a seasoned management team, Velocimed creates products internally and also looks externally for new technologies by partnering with physicians, inventors and institutions -- particularly those who may lack access to the necessary resources required for early development of new ideas. At Velocimed, they believe that they own a unique position in medical innovation and commercialization. Unlike small incubators, they have the expertise to commercialize viable technology. And unlike large companies, they have the ability to pinpoint opportunities faster and move more quickly.

Vascular Architects Inc., established in 1997 by renowned surgeon Dr. Thomas J. Fogarty, specializes in designing, manufacturing, and marketing innovative devices for treating vascular stenoses, occlusions, and non-vascular obstructions. Their primary focus is on peripheral vascular disease, which involves reduced or lost blood flow due to narrowed or closed arteries. The company's product portfolio includes intraoperative vascular instruments like Doppler probes, laparoscopic Doppler systems, and oxygen analyzing monitors, used across various surgical specialties such as cardiovascular, urology, gynecology, neurology, and plastic surgery. Vascular Architects is led by an experienced team of technical, clinical, and business professionals, with key opinion leaders in interventional and vascular surgery communities serving on their Scientific Advisory Board.

BioSET, Inc., founded in 2001 and based in Rockville, Maryland, specializes in the research and development of synthetic bioactive peptides aimed at enhancing bone and soft tissue repair. The company creates proprietary therapeutic peptides utilized as medical devices in orthobiologics applications. Its notable product, Amplex, is an implantable device that combines a peptide with a synthetic ceramic scaffold, designed for use in spinal fusion surgeries and other orthopedic procedures. Additionally, BioSET develops products for sports medicine and creates peptide signaling molecules along with various scaffold biomaterials for applications in trauma, fracture repair, and soft tissue treatments. As of February 2015, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.

PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

OsteoBiologics is a biotechnology company. It engages in the development and manufacture of bio-absorbable polymeric scaffolds, films, and related instrumentations for the repair and replacement of bone, soft tissue, and articular cartilage. It provides ACTAEON, a tissue evaluation system, which determines the degree and scope of articular cartilage degeneration. It also manufactures custom parts. OsteoBiologics was founded in 1993 and is headquartered in San Antonio, Texas.

Bacchus Vascular, Inc. is a medical device company based in Santa Clara, California, specializing in the treatment of occlusive vascular disease. Founded in 1999, the company develops innovative therapeutic solutions for interventional radiologists and vascular surgeons in the United States. One of its key products is the TRELLIS-8 Peripheral Infusion System, which features an isolated thrombolysis catheter designed for the targeted delivery of clot-dissolving drugs to treat conditions such as deep vein thrombosis and arterial occlusions. Additionally, Bacchus Vascular is involved in procedures for the percutaneous removal of blood clots from both dialysis and peripheral grafts, as well as native arteries and veins, further addressing the needs of patients with vascular complications.

Velocimed was founded by a group of well known medical entrepreneurs. The company's founders envisioned a company that would become a global leader in the identification and development of innovative technologies with the power to improve the lives of patients whose clinical needs are not being met. Lead by a seasoned management team, Velocimed creates products internally and also looks externally for new technologies by partnering with physicians, inventors and institutions -- particularly those who may lack access to the necessary resources required for early development of new ideas. At Velocimed, they believe that they own a unique position in medical innovation and commercialization. Unlike small incubators, they have the expertise to commercialize viable technology. And unlike large companies, they have the ability to pinpoint opportunities faster and move more quickly.

Vascular Architects Inc., established in 1997 by renowned surgeon Dr. Thomas J. Fogarty, specializes in designing, manufacturing, and marketing innovative devices for treating vascular stenoses, occlusions, and non-vascular obstructions. Their primary focus is on peripheral vascular disease, which involves reduced or lost blood flow due to narrowed or closed arteries. The company's product portfolio includes intraoperative vascular instruments like Doppler probes, laparoscopic Doppler systems, and oxygen analyzing monitors, used across various surgical specialties such as cardiovascular, urology, gynecology, neurology, and plastic surgery. Vascular Architects is led by an experienced team of technical, clinical, and business professionals, with key opinion leaders in interventional and vascular surgery communities serving on their Scientific Advisory Board.

PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

BioSET, Inc., founded in 2001 and based in Rockville, Maryland, specializes in the research and development of synthetic bioactive peptides aimed at enhancing bone and soft tissue repair. The company creates proprietary therapeutic peptides utilized as medical devices in orthobiologics applications. Its notable product, Amplex, is an implantable device that combines a peptide with a synthetic ceramic scaffold, designed for use in spinal fusion surgeries and other orthopedic procedures. Additionally, BioSET develops products for sports medicine and creates peptide signaling molecules along with various scaffold biomaterials for applications in trauma, fracture repair, and soft tissue treatments. As of February 2015, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.

CardioThoracic Systems designs, develops, and manufactures surgical products and systems for minimally invasive cardiac surgery. The Company's current products are designed to enable the majority of cardiothoracic surgeons, using their existing skills coupled with company-sponsored training, to perform MICS on a beating heart. The OPCAB (Off Pump Coronary Artery Bypass) and MIDCAB (Minimally Invasive Direct Coronary Artery Bypass) procedures eliminate the need for a heart-lung machine, and recent studies indicate that the MICS procedures reduce the trauma, procedural costs and post-surgical complications associated with conventional coronary artery bypass graft (CABG) surgery while providing long-term procedural success rates comparable to CABG surgery. CardioThoracic Systems was founded in 1994 and is based in Cupertino, California. As of November 15, 1999, CardioThoracic Systems, Inc. was acquired by Guidant Corp.